Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract

✍ Scribed by Alec S. Goldenberg; David Kelsen; James Dougherty; Gordon Magill

• Publisher: Springer US
• Year: 1990
• Tongue: English
• Weight: 412 KB
• Volume: 8
• Category: Article
• ISSN: 0167-6997
• DOI: 10.1007/bf00216927

✦ Synopsis

Iproplatin (CHIP) is a second generation cisplatin analogue which has completed its Phase I trials. We studied the efficacy and toxicity of CHIP in 36 previously untreated patients with advanced upper gastrointestinal tract adenocarcinomas (GE junction, cardia, antrum and body of the stomach). The starting dose was 275 mg/m2; course were repeated on an every four week schedule. Thirty-five patients were evaluable for response. Three partial remissions (8.5%) [95% confidence limits 2.5-15%] were seen. Toxicity was tolerable and included mild myelosuppression and mild nausea and vomiting. Although well tolerated, in patients with gastric and GE junction adenocarcinomas, CHIP chemotherapy was not more and probably slightly less, effective than the parent analogue cisplatin.